key: cord-0765735-mx4rrwpb
authors: Melmed, Gil Y.; Rubin, David T.; McGovern, Dermot P.B.
title: Winter is coming! Clinical, immunological, and practical considerations for vaccinating patients with IBD during the COVID pandemic
date: 2020-10-14
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.10.013
sha: 2883292242f4a89136e972e694623842ed1926b2
doc_id: 765735
cord_uid: mx4rrwpb

nan

As summer turns to fall, clinicians' minds usually turn to the upcoming winter season and preparing for winter infections, particularly influenza. In 2020, though, we face a new and formidable foe: SARS-CoV-2. While we hope that an effective vaccine against SARS-CoV-2 will soon be available, distribution of an effective vaccine is not likely to occur soon, so it is especially appropriate to use the other tools already at our disposal to keep our patients with IBD well. This includes making sure that our patients are in stable steroid-free remission, but also guaranteeing that they are updated regarding other vaccinations. We need to ensure that our patients are educated and encouraged to receive the influenza vaccination as well as vaccinations against pneumococcal infection. Discriminating COVID-19 from influenza or other respiratory infections based on symptoms alone will be difficult and concomitant infection with SARS-CoV-2 and other respiratory pathogens will likely increase morbidity and mortality. In this commentary, we outline the utility and rationale for existing practices related to vaccinepreventable illnesses in IBD, and discuss the emerging science and ethical challenges related to the highly anticipated vaccines against SARS-CoV-2.

Many studies have evaluated the efficacy of vaccines among patients with IBD, including those on different immunomodulatory regimens. 1, 2 There are several important messages to be learned from these studies. First, vaccine efficacy may be blunted by immunomodulators, some biologics, and corticosteroids. However, a blunted response does not necessarily translate to vaccine inefficacy, and partial protection is better than none. Therefore, vaccines should not be withheld just because a patient is receiving immunosuppressive treatment for their IBD. 3 Second, vaccination while on immunosuppressive treatments may be associated with an accelerated waning of protective antibody titers. 4, 5 The implications of this phenomenon are not entirely J o u r n a l P r e -p r o o f clear, although for some infections like hepatitis B, it may be appropriate to assess postvaccination titers and consider additional booster dosing for low or absent titers. 4 Third, predictors of efficacy relevant to the general population are also applicable to those with IBD.

These may include age, gender, body mass index, prior infection, immune compromise or senescence, and genetic polymorphisms. 6 Older patients are generally more vulnerable to infections, and the ability to mount a robust vaccine response tends to decrease with age. Genetic polymorphisms may be associated with blunted vaccine responses, although it is unclear how these translate into differences in efficacy. Finally, the risk of an IBD relapse from vaccination is reassuringly negligible; published evidence to date does not suggest an association between any specific vaccine and exacerbation of IBD.

This year, because of clinical similarities between COVID-19 and influenza, vaccination against influenza is a critically important public health recommendation and highly relevant for patients with IBD who are both at increased risk for acquiring influenza and at increased risk from complications thereof. 7 Vaccination against influenza is recommended annually due to antigenic drift, or mutations in the surface hemagglutinin or neuraminidase proteins involved in host recognition of the viral particle which render each season's influenza viruses sufficiently different from past viruses to evade previous host immunity. Despite the variable effectiveness of the vaccine, influenza vaccination has been shown to reduce the signs and symptoms of the flu, reduce hospitalizations, reduce mortality in children and adults, prevent disease in those with chronic health conditions, protect women during and after pregnancy, reduce the severity of the flu among those with partial immunity, and provide herd immunity for those susceptible to infection. [8] [9] [10] [11] For the 2020-2021 season, both trivalent and quadrivalent vaccines have been developed based on WHO recommendations. 12 These vaccines are available as high dose J o u r n a l P r e -p r o o f vaccines (for those age >65), egg-free (for those with egg allergies), and as a live-attenuated nasal vaccine. All individuals older than 6 months are advised to receive influenza vaccination with any of the approved formulations. For patients with IBD on immunosuppressive therapies, any inactivated vaccine would be appropriate, but the live-attenuated intranasal formulation is not. High-dose and quadrivalent influenza vaccines have been evaluated in patients with IBD, and should be considered, especially among those older than 65. 13 Pneumococcal vaccination is recommended for patients with IBD, especially if on immunosuppression or age >60 years. 14 Pneumococcal vaccination is available as a 23-valent polysaccharide vaccine, and a 13-valet conjugate vaccine. Immunosuppressed patients should receive the conjugate vaccine, followed by the polysaccharide vaccine at least 8 weeks later, and a polysaccharide vaccine booster every 5 years. 15

The international effort to deploy safe and effective vaccines against SARS-CoV-2 is 

Non-replicating (simian or human) viral vector vaccines in which viruses are engineered to carry coronavirus genes (CanSino Biologics -Adenovirus type 5 vector:

Gamaleya Research Institute -Adenovirus-based vector: Astra-Zeneca/University of Oxford -Simian ChAdOx1-S vector).

Vaccines that contain whole or fragments of coronavirus proteins such as the 'Spike' protein and often administered together with an adjuvant to enhance immune responses (none in phase 3 currently and a number in Phase 2).

Products/Sinopharm; Beijing Institute of Biological Products/Sinopharm).

In addition to these novel approaches, a number of groups are looking to repurpose existing vaccines, the most high-profile of which is the anti-tuberculosis Bacillus Calmette-Guerin (BCG) vaccine, currently in phase 3 studies (BRACE trial, Murdoch Children's Research Institute, Australia). The rationale for BCG includes intriguing epidemiological data suggesting decreased mortality from COVID-19 in populations previously exposed to BCG. 16 Beyond safety it will of course be important to evaluate vaccine efficacy in patients with IBD given experience with other vaccines. How efficacious are the vaccines in the setting of systemic inflammation or immunotherapy? Will higher doses or additional boosters be needed, and how long will immunity last? Do distinct vaccine modalities induce differences in the degree and/or duration of immunity in patients with immune mediated diseases? It is also still unknown which measure of humoral and cellular immune responses will best determine immunity and whether this will be different in patients with IBD. To answer these and questions about safety, it is vital that patients with IBD be closely monitored and studied in prospective cohorts with serial assessments after receiving any vaccine.

There are a number of ethical considerations to the development and distribution of vaccinations for SARS-CoV-2 that must be considered and are similar to considerations for any new medical intervention and for any limited resource. First, as mentioned above and specifically related to beneficence and non-maleficence, because patients with immune conditions, including those with IBD, are excluded from the clinical trials of vaccine effectiveness and safety, extrapolation of results from such trials will be necessary. Additional post-marketing studies will be necessary in such populations. While our understanding of existing vaccines in patients with IBD will likely translate to these new vaccines, there will remain important studies that must occur.

Second, is the ethical issue of justice, and allocation of a scarce resource. We will need to grapple with decisions about who should receive the vaccines, which will likely have distribution and availability limitations initially. The CDC has proffered a tiered approach (Tier 1 high priority, Tier 5 low priority) for vaccine distribution based on population categories and severity of the pandemic (low to very high severity). 20 In their table, most health care workers are considered Tier 1 and would receive the vaccine early for any degree of severity of the pandemic. Among patient types, pregnant women, infants and toddlers are also considered Tier 1 for all degrees of severity of the pandemic. Adults age 19-64 years old with high risk conditions are tier 2 for low severity pandemic, but tier 3 and 4 for moderate or high/very high severity pandemic. It is likely that patients with IBD, despite the available data that suggest that they are not at high risk for adverse COVID-19 outcomes, will be stratified into the high-risk population.

It is essential that we continue to educate our patients with IBD about their actual risks based on available and reassuring data. 21 It is expected that there will be a great demand for the vaccines. As healthcare providers and physician leaders, it is our responsibility to manage the needs of our most at-risk patients and to distribute a limited resource equitably. 22 This translates into an approach such that older patients with IBD, patients who are steroid-dependent, and those with other established COVIDrelevant co-morbidities (obesity, hypertension, diabetes, etc) should receive vaccines before other patients. Additional factors of consideration will be based on regional prevalence of COVID-19 and then separately, ethnicity and race, recognizing the data of increased risk of infection and adverse outcomes in black and Latinx populations. The risk of infection and adverse outcomes should be evaluated in conjunction with practical considerations of access to healthcare access. Nationally organized updates and a national surveillance plan for SARS-CoV-J o u r n a l P r e -p r o o f 2 prevalence will be needed, and in the absence of such organization, local and regional public health officials should guide distribution and provide regular updates.

Finally, it is essential that we actively address misinformation and conspiracy theories about vaccinations in general, and about the new SARS-CoV-2 vaccines. It is unfortunate that the scientific method and regulatory pathways for medical therapies and vaccines have become politicized and even discarded. We must promote reliable, scientifically rigorous information and consider the public health implications of an effectively vaccinated population. This will include highlighting limitations to the datasets and advocating on behalf of our patients if there is insufficient information from which to draw conclusions. Specifically, we should proactively remind our patients that IBD is not caused or exacerbated by vaccinations, and that the SARS-CoV-2 vaccines will not have risk of causing COVID-19.

The information about SARS-CoV-2 and IBD is evolving rapidly, but there remain many uncertainties, and a pressing need for ongoing research. What is the true prevalence of anti-SARS-CoV-2 in the IBD population and how does that compare with non-IBD populations? A recent study from Germany demonstrated low SARS-CoV-2 seroconversion in anti-cytokine exposed patients with immune-mediated conditions, but the reasons for this finding are not known. 23 immunization. We must also be ready to respond to anti-vaccination tropes and non-scientifically valid arguments against preventive immunizations. Second, we should stay apprised of the progress of SARS-CoV-2 vaccines and anticipate that our patients will look to us for guidance.

Thus far, we can reassure our patients that the major candidate vaccine mechanisms appear safe for most, if not all patient populations, but that further clarity may be needed among those who are immunosuppressed. While it is unlikely that any vaccine will be 100% effective against SARS-CoV-2 transmission, the most effective prevention strategy will include both vaccination and continued hygiene practices including handwashing and judicious masking and physical distancing. Third, we must acknowledge that the initial demand for vaccines will exceed supply, and that a tiered approach to vaccine prioritization is ethically valid. This will involve prioritizing healthcare workers, vulnerable populations with increased risk for COVID-19

complications. Finally, we should seek opportunities within the IBD community to enroll patients in post-marketing registries to better understand the effects of SARS-CoV-2 vaccines on J o u r n a l P r e -p r o o f various IBD population profiles and establish evidence to further guide optimal vaccination strategies for our patients with IBD. Winter may be coming, but can Spring be far behind? 25 J o u r n a l P r e -p r o o f 

Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease

Vaccinations while on thiopurines: some protection is better than none

Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease

Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis

Influenza vaccine failure: failure to protect or failure to understand?

Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease

Estimated influenza illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season

Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies

Influenza vaccination of pregnant women and protection of their infants

Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand

Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial

ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease

BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)

COVID-19 Vaccine: A comprehensive status report

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, nonrandomised phase 1/2 studies from Russia

But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Fairly Prioritizing Groups for Access to COVID-19 Vaccines

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients

Ode to the West Wind. Prometheus Unbound

Author names in bold designate shared co-first authorship.J o u r n a l P r e -p r o o f